Mitsubishi Corporation

Skip to Main



This page is Home>Discovering our Potential>Biopharmaceuticals.


Potential - Biopharmaceuticals

Working with Excellent Companies Possessing Advanced Biopharmaceuticals Manufacturing Technologies

Under an equity-based business alliance with FUJIFILM Corporation, we have invested in a business custom manufacturing biopharmaceuticals using advanced biotechnologies. Our aim is to tap into the market for unmet medical needs, which is expected to grow going forward. Unmet medical needs cannot be effectively treated with existing treatments.

Global Pharmaceuticals Market (Prescription drug basis) ($ billion)
Global Pharmaceuticals Market (Prescription drug basis)

The Chemicals Group has, to date, amassed much insight in the biopharmaceuticals sector through its investments in bioventures. This has enabled it to build a network in the industry. We have also carried our custom manufacturing of intermediates and sold active pharmaceutical ingredients in our small molecule drugs* business for many years. Through these activities, we have built relationships with major pharmaceuticals firms in Japan, the U.S. and Europe. We are also deeply involved in companies selling generic drugs, having established joint ventures with partners.

As a new undertaking, in June 2011, we formed an alliance with FUJIFILM Corporation to enter the business of custom manufacturing biopharmaceuticals. Biopharmaceutical is a general term for pharmaceuticals applying constituents found in the human body. In therapeutics areas where there are high unmet medical needs such as cancer and rheumatoid arthritis, and where effective therapies still don't exist, the market for effective medical treatments is expected to grow going forward. The manufacture of biopharmaceuticals requires sophisticated biotechnologies, including gene recombination and cell culturing. The two FUJIFILM Diosynth Biotechnologies companies MC has invested in under the alliance agreement possess advanced biopharmaceuticals manufacturing technologies. MC aims to capture business in the contract manufacturing sector, a market that is expected to grow by at least 15% annually.

* Conventional pharmaceuticals created from chemical synthesis

[From the Business Frontline]

This is a cooperative project in the advanced field of biopharmaceuticals between MC and FUJIFILM.

The alliance will draw on the strengths of each company—FUJIFILM's advanced technologies and MC's global business-making capabilities—to expand business. This project will contribute through biopharmaceuticals to the development of a new business domain and address unmet medical needs. In doing so, I strongly hope that we can help improve people's quality of life.

Pharmaceuticals Team Leader, Bio-Fine Chemicals Unit
Maki Hosoda